| 裴夫瑜 李七 许文峰 吴学东 何岳林 冯晓勤 李春富△.异基因造血干细胞移植治疗儿童白血病87 例临床分析[J].,2016,16(18):3485-3488 |
| 异基因造血干细胞移植治疗儿童白血病87 例临床分析 |
| Clinical Analysis of 87 Cases of Childhood Leukemia Treated withHematopoietic StemCell Transplantation |
| |
| DOI： |
| 中文关键词: 白血病 儿童 异基因 造血干细胞移植 |
| 英文关键词: Leukemia Children Allogeneic Hematopoietic stemcell transplantation |
| 基金项目: |
|
| 摘要点击次数: 735 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：评估异基因造血干细胞移植(allogeneic hematopoieticstemcell transplantation, Allo-HSCT)治疗儿童急慢性白血病的效
果及相关影响因素。方法：回顾性分析我科2006 年2 月至2012 年2 月间，采用Allo-HSCT治疗儿童急慢性白血病87 例临床资
料，按照白血病类型分为BCR/ABL+ ALL、BCR/ABL- ALL、AML、CML 组，通过单因素分析和多因素分析考察白血病类型、移植
前状态、是否服用伊马替尼治疗和干细胞源等因素对Allo-HSCT 治疗效果的影响。结果：所有入组白血病患儿接受Allo-HSCT治
疗后，整体生存率(overall survival，OS)59.7%。单因素分析结果显示白血病类型(P=0.023)、aGVHD、服用伊马替尼、移植前状态(P =
0.025) 和干细胞来源(P=0.003) 对患者的整体生存率影响具有统计学意义。多因素分析结果显示干细胞源（PBSC、UCB、BM、
BM+PBSC、BM/PBSC+UCB，P=0.046）、移植前状态（CR1、CR2、CR3、NR，P=0.048）和移植种类(同胞、非亲缘、单倍体，P=0.023)能
够显著影响OS；而疾病类型（ALL、AML、CML，P=0.083）、性别（P=0.968）、年龄（P=0.847）与生存率关系没有统计学意义。结论：白
血病类型、移植种类、aGVHD、干细胞源、是否服用伊马替尼和移植前状态是影响异基因造血干细胞移植治疗小儿白血病疗效的
关键因素。 |
| 英文摘要: |
| Objective:To evaluate the effect of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) for children with
leukemia and investigate its related influence factors.Methods:The clinical data of 87 patients with leukemia underwent HSCT at a
median age of 8 years from February 2006 to December 2013 in our centerwere retrospectively analyzed, these patients were divided into
BCR/ABL+ ALL, BCR/ABL- ALL, AML and CML groups according to Leukemia types.Results:The estimated 5-year overall survival
(OS) was 59.7 % in total. Single factor analysis showed leukemia types(P=0.023), imatinib(P=0.008), aGVHD (P=0.001), status before
transplantation (P=0.025), stem cell source (P=0.003) had significant impact on the overall survival. Multivariate analysis showed stem
cell source (P=0.046), status before transplantation (P=0.048) and the transplant types (P=0.023) had significant impact on OS
significantly while age, sex and leukemia types had no obvious impact OS.Conclusion:The leukemia types, imatinib, aGVHD, status
before transplantation, stemcell source and transplant type were key influence factors of Allo-HSCT for pediatric leukemia. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
